Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07165132 · ClinicalTrials.gov registry record · Phase 1
Study of RYZ401 in Subjects With Solid Tumors Expressing SSTRs.
A Phase 1 study, sponsored by RayzeBio.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 104
- Enrollment target
NCT07165132 is a Phase 1 study that is actively recruiting participants, run by RayzeBio. The registered enrollment target is 104 participants.
The verdict
NCT07165132, a Phase 1 study, is actively recruiting participants, sponsored by RayzeBio.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 104 participants
- Enrollment target
Study Summary
The primary objectives are to determine the recommended Phase 2 dose (RP2D) and optimal treatment regimen, characterize safety and tolerability, and evaluate preliminary efficacy of RYZ401 in subjects with NETs and other selected solid tumors expressing SSTRs.
Interventions
- DRUG RYZ401
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 104 participants |
| Start Date | 2025-12-03 |
| Est. Completion | 2033-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07165132
The ClinicalTrials.gov registry entry for NCT07165132 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 104 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is RayzeBio, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which RYZ401 is the first listed.
NCT07165132 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07165132 about?
NCT07165132 is a clinical study titled "Study of RYZ401 in Subjects With Solid Tumors Expressing SSTRs.". The primary objectives are to determine the recommended Phase 2 dose (RP2D) and optimal treatment regimen, characterize safety and tolerability, and evaluate preliminary efficacy of RYZ401 in subjects with NETs and other selected solid tumors expressing SSTRs.
What is the current status of trial NCT07165132?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 104 participants. The study started on 2025-12-03. Estimated completion is 2033-04.
What interventions are being tested in trial NCT07165132?
The interventions under investigation include: RYZ401 (DRUG).
Who is sponsoring clinical trial NCT07165132?
This trial is sponsored by RayzeBio, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.